Junji Gene (苏州君跻基因科技有限公司) is building an automated, AI-enabled platform that covers Sanger sequencing, oligonucleotide synthesis, high-throughput gene synthesis, gene editing and protein expression. Its proprietary production lines run 24/7 with higher efficiency and success rates than traditional manual workflows, positioning the company as an early mover in ‘lights-out’ smart factories for gene technologies. The firm also invests in next-generation gene synthesis, small-nucleic-acid conjugation, and its NGSafety® platform for quality and safety analysis of cell and gene therapies. Commercialization is underway through a dual-center strategy of domestic automated manufacturing and an overseas sales network that already serves leading biopharma enterprises, research institutes and diagnostics companies. The core team averages more than ten years of experience across gene technology and automation, enabling rapid scale-up and data feedback loops that further improve AI algorithms. Capital from the latest round will fund production-line upgrades, continued R&D, team expansion and global market penetration. Although no revenue or user figures were disclosed, management positions the company as a foundational infrastructure provider for the "AI + life science" era.

Total raised

$14M

Funding rounds

2

Latest round

Series A

Latest activity

Dec 2025